Cargando…

Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China

BACKGROUND: This study aimed to investigate the cost-effectiveness of dacomitinib and gefitinib for the first-line treatment of advanced non-small-cell lung cancer (NSCLC) in epidermal growth factor receptor (EGFR) mutation-positive patients from the perspective of healthcare systems in the United S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Xinglu, Fang, Nan, Li, Huanan, Liu, Yanyan, Yang, Fan, Li, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246172/ https://www.ncbi.nlm.nih.gov/pubmed/34268373 http://dx.doi.org/10.21037/atm-20-6992

Ejemplares similares

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
por: Zhang, Longfeng, et al.
Publicado: (2021)

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
por: Mok, Tony S., et al.
Publicado: (2020)

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
por: Kudo, Kenichiro, et al.
Publicado: (2020)

Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations
por: Li, Jerry, et al.
Publicado: (2021)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

Modelled Economic Analysis for Dacomitinib–A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China
por: Yu, Yong-feng, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
por: Douillard, J-Y, et al.
Publicado: (2014)

A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations
por: Li, Hong‐Shuai, et al.
Publicado: (2022)

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
por: Li, Yibin, et al.
Publicado: (2022)

Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
por: Morita, Ayako, et al.
Publicado: (2021)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
por: Pu, Xingxiang, et al.
Publicado: (2023)

Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
por: Kwok, Wang Chun, et al.
Publicado: (2022)

Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study
por: ABDULLAH, MATIN MELLOR, et al.
Publicado: (2016)

A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report
por: Zhou, Tao, et al.
Publicado: (2022)

Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study
por: Li, Hong-Shuai, et al.
Publicado: (2022)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
por: Yang, Chih-Jen, et al.
Publicado: (2017)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer
por: Nishio, Makoto, et al.
Publicado: (2020)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
por: Nan, Xueli, et al.
Publicado: (2017)

Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China
por: Guan, Haijing, et al.
Publicado: (2022)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations
por: Van Luan, Pham, et al.
Publicado: (2021)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment
por: Li, Hong-Shuai, et al.
Publicado: (2021)

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib
por: Piscitelli, Joseph, et al.
Publicado: (2022)

Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304)
por: Song, Yong, et al.
Publicado: (2019)

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
por: Xin, Shuang, et al.
Publicado: (2015)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
por: Li, Meng-Xia, et al.
Publicado: (2017)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
por: Shu, Yamin, et al.
Publicado: (2022)

Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations
por: Li, Junzhe, et al.
Publicado: (2023)

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations
por: Song, Ruiqiang, et al.
Publicado: (2022)

Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study
por: Lu, Shun, et al.
Publicado: (2021)

Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2015)

Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro
por: Ji, Weiping, et al.
Publicado: (2021)

Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells
por: Bokobza, Sivan M., et al.
Publicado: (2014)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib
por: Yang, Li-Li, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7ok0ed0a1rk5l3jcvejj25jmbc